.. (at least to me) is the volume done on AMRN .. and what it reveals (currently and over the coming weeks)

Detailed Quote:AMRN
AMARIN CORP PLC
12.40Up 9.41 (314.72 %)AS OF 4:00:00PM ET 09/24/2018

Last Trade 12.40
Trade Time 4:00:00pm ET

Change 9.41
% Change 314.72%

Bid 12.52
Bid Size 2

Ask 12.57
Ask Size 1

Open 10.44
Day High 12.47
Day Low 9.51
Previous Close
09/21/2018 2.99
52-Week High
09/24/2018 12.47
52-Week Low
07/31/2018 2.35

Price Performance (Last 52 Weeks)
09/21/2018 -7.72%

Volume 162,445,938
Volume (10 day Average) 3,543,201
Volume (90 day Average) 2,944,746

Options Yes
Market Capitalization $886.08M
Shares Outstanding 296,349,000

4kids

Quote:

Interesting speculation by CITI on AMRN today:

Citi sees another 5x upside in Amarin
Sep. 24, 2018 11:53 AM ET|By: Stephen Alpher, SA News Editor
Amarin (NASDAQ:AMRN) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.

Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: Notable Calls

Also on the move on the news is Acasti Pharma (ACST +26.9%), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.

Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)

If they are worth $50.00 in a buyout with a single drug just imagine what we will be worth with multiple blockbusters! Just goes to show how undervalued we are at this time. Go IPIX!!!